Identification of a small molecule inhibitor of 3-phosphoglycerate dehydrogenase to target serine biosynthesis in cancers
Cancer cells reprogram their metabolism to promote growth and proliferation. The genetic evidence pointing to the importance of the amino acid serine in tumorigenesis is striking. The gene encoding the enzyme 3-phosphoglycerate dehydrogenase (PHGDH), which catalyzes the first committed step of serine biosynthesis, is overexpressed in tumors and cancer cell lines via focal amplification and nuclear factor erythroid-2-related factor 2 (NRF2)-mediated up-regulation. PHGDH-overexpressing cells are exquisitely sensitive to genetic ablation of the pathway. Here, we report the discovery of a selective small molecule inhibitor of PHGDH, CBR-5884, identified by screening a library of 800,000 drug-like compounds. CBR-5884 inhibited de novo serine synthesis in cancer cells and was selectively toxic to cancer cell lines with high serine biosynthetic activity. Biochemical characterization of the inhibitor revealed that it was a noncompetitive inhibitor that showed a time-dependent onset of inhibition and disrupted the oligomerization state of PHGDH. The identification of a small molecule inhibitor of PHGDH not only enables thorough preclinical evaluation of PHGDH as a target in cancers, but also provides a tool with which to study serine metabolism.
PHGDH | inhibitor | serine | cancer metabolism S erine is required for a plethora of anabolic processes. Serine is an abundant component of proteins and is required for the synthesis of lipids, including sphingolipids and phosphatidylserine, a major component of cellular membranes (1) (2) (3) . Alternatively, serine hydroxymethyltransferases (SHMTs) convert serine to glycine, concomitantly charging the folate pool with "one-carbon" units (4, 5) . Both glycine and folate one-carbon units are used to make nucleotides. Thus, serine serves numerous critically important roles in cellular metabolism.
At the cellular level, serine can be imported from the extracellular space via amino acid transporters (6, 7) . Alternatively, serine can be synthesized from glucose via the phosphoserine pathway (8) . De novo synthesis proceeds from the glycolytic intermediate 3-phosphoglycerate (3-PG) via three sequential enzymatic reactions (Fig. 1A) , the first of which is catalyzed by the NAD + -dependent enzyme 3-phosphoglycerate dehydrogenase (PHGDH) (9) . For decades, it has been known that cancer cells have enhanced serine synthesis, which contributes to nucleotide synthesis (10, 11) . Recently, focal amplifications of the gene encoding PHGDH have been reported, particularly in breast cancers and melanomas (12) (13) (14) . Additionally, KEAP1 and nuclear factor erythroid-2-related factor 2 (NRF2) mutant non-small cell lung cancers (NSCLCs) overexpress PHGDH (15) . Proliferation of PHGDH-amplified cancer cell lines, and other lines that overexpress PHGDH without amplification, is inhibited by PHGDH knockdown. In contrast, lines that express little PHGDH are resistant to shRNA-mediated ablation of the pathway, presumably because serine import suffices (13, 14) . A detailed mechanistic understanding of why some cancer cells are addicted to serine synthesis despite the availability of extracellular serine for import remains unclear. Interestingly, in triple negative breast cancer (TNBC) and NSCLC, PHGDH amplification and overexpression are associated with more aggressive disease (13) (14) (15) (16) . Thus, PHGDH
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The studies herein detail our efforts in identifying small molecule inhibitors of PHGDH. We reasoned that a PHGDH inhibitor would have the benefits of not only providing a tool compound with which to study the biology of serine synthesis, but also enabling thorough preclinical evaluation of PHGDH as a target in cancers. We screened a library of 800,000 small molecules using an in vitro PHGDH assay. A cell-based assay for serine synthesis was used to identify a lead, CBR-5884, that was active in cells. CBR-5884 selectively inhibited the proliferation of melanoma and breast cancer lines that have a high propensity for serine synthesis but had no effect on lines that rely on extracellular serine uptake. Mechanistically, CBR-5884 was found to be a noncompetitive inhibitor, showed a time-dependent onset of inhibition, and disrupted the oligomerization state of PHGDH.
Results
Screening for Small Molecule Inhibitors of PHGDH. An in vitro enzymatic assay for PHGDH activity amenable to high-throughput screening (HTS) was developed by coupling the production of NADH, upon 3-PG oxidation, to the reduction of resazurin to resorufin using diaphorase as the coupling enzyme (Fig. 1B) . Thus, resorufin fluorescence served as a proxy for PHGDH activity. The assay was miniaturized to a 1,536-well format with a Z-factor of >0.75, indicating a high quality assay (17) . A library of 800,000 small molecules was screened in single point format at 13 μM (Fig. 1C) . Setting a threshold Z score of −3, corresponding to at least 50% PHGDH inhibition, gave a 0.5% hit rate, yielding 3,906 hits. Putative hits were reassayed in triplicate and counter-screened against diaphorase to rule out false positives targeting diaphorase. The counter screen eliminated 3,498 compounds, giving 408 PHGDH inhibitors (Fig. 1D) .
A triaging strategy based on hit potency and selectivity was designed. We reasoned that inhibitors specific to PHGDH would minimize general cellular toxicity compared with compounds that hit a variety of dehydrogenases. Thus, half maximal inhibitory concentrations (IC 50 ) were determined for a panel of NAD(P) + -dependent dehydrogenases that included PHGDH, isocitrate dehydrogenase (IDH1), malate dehydrogenase (MDH1), and 3α-hydroxysteroid dehydrogenase (3α-HSD). Compounds at least fourfold more selective for PHGDH were progressed for further analysis. Based on this triaging, seven of the most potent PHGDH inhibitors were selected as lead compounds for evaluation in cell-based assays; selected structures are shown in Fig. 1E ( Table S1 ). A number of these compounds are likely to target sulfhydryl groups and may therefore react with a PHGDH cysteine residue. For example, both CBR-5807 and CBR-6936 contain sulfhydryl-reactive disulfide centers. Interestingly, CBR-5807 (Disulfiram) is an approved drug dosed in humans to treat alcoholism and known to inhibit aldehyde dehydrogenase by reacting with sulfhydryl groups (18) .
CBR-5884 Inhibits Serine Synthesis in Cells.
We determined whether any of our seven leads inhibited serine synthesis in cancer cells. To do so, we turned to gas chromatography mass-spectrometry (GCMS) with uniformly carbon-13-labeled glucose ( 13 C 6 -glucose) tracing. Given the isotopic enrichment of serine, it is possible to decouple newly synthesized serine from extracellular serine or serine that was synthesized before tracer addition. Newly synthesized serine has a mass-shift of 3 (M+3) due to the incorporation of glucose-derived 13 C via 3-PG. We first investigated the kinetics of serine labeling. Serine labeling plateaued around 6 h, with ∼65% of the serine pool being 13 C-labeled (Fig. S1 ). The plateau phase likely reflects exchange between intra-and extracellular serine pools (19) .
With an understanding of serine-labeling kinetics, we designed a 13 C 6 -glucose tracing assay to acutely interrogate the effects of compounds on serine synthesis ( Fig. 2A) . Assaying serine synthesis with a 3-h compound treatment was preferred to longer treatments to guard against false positives that decrease serine labeling by an indirect effect, such as generally compromising cellular viability. Among our lead compounds, CBR-5884 was able to decrease de novo serine synthesis by 30%; the remaining compounds had little effect (Fig. 2B) . The dose at which CBR-5884 had an effect on serine labeling was consistent with the in vitro biochemical IC 50 of 33 ± 12 μM for PHGDH (Fig. 2C ). At such concentrations, CBR-5884 had no effect on two other NAD + -dependent dehydrogenases, lactate dehydrogenase (LDH) and MDH1 ( Fig.  2C and Fig. S1 ). Importantly, under the acute treatment time period used in the labeling assays, CBR-5884 was not generally cytotoxic at concentrations up to 40 μM as determined by two independent cellular viability assays (Fig. S1 ). Therefore, decreases in serine labeling are a direct effect of CBR-5884-mediated PHGDH inhibition.
We resynthesized CBR-5884 in-house and performed a doseresponse experiment for CBR-5884 using the same acute treatment method as above. Serine labeling was significantly decreased at 30 μM and trended toward a decrease at 15 μM (Fig. 2D) . Importantly, perturbations in labeling were specific to serine in that neither the PHGDH substrate, 3-PG, nor the end products of ; phosphoserine amino transferase (PSAT1) transaminates p-Pyr to phosphoserine (p-Ser) using glutamate as a nitrogen donor; phosphoserine phosphatase (PSPH) dephosphorylates p-Ser to yield serine. (B) In vitro PHGDH assay. Diaphorase couples the NADH produced upon PHGDH turnover to the reduction of resazurin to fluorescent resorufin. Resorufin fluorescence is a proxy for PHGDH activity. PSAT1 is included to prevent product feedback inhibition of PHGDH by p-Pyr. (C) Z-score plot for the 800,000-compound library screened using the above PHGDH assay. Each point represents a single compound. A negative score indicates inhibition. (D) Screen triaging strategy. Setting a Z-score threshold of −3 gave 3,906 putative hits. After counter-screening against diaphorase to rule out false positives and confirming activity against PHGDH, 408 compounds remained. Selected compounds were profiled against a panel of metabolic NAD(P) + dehydrogenases to ascertain selectivity for PHGDH. (E) Structures of representative PHGDH inhibitors evaluated in cell-based assays.
glycolysis, pyruvate and lactate, were affected (Fig. 2D) . We further confirmed that glycolytic metabolites were unperturbed by CBR-5884 treatment using liquid chromatography mass spectrometry (LC-MS/MS) to interrogate a greater panel of metabolites (Fig.  S1 ). Thus, changes in serine labeling are a direct effect of CBR-5884-mediated PHGDH inhibition and not a consequence of changes in PHGDH substrate levels or general perturbations in glycolytic flux (Fig. 2D) . The absence of an effect on lactate labeling was consistent with the in vitro data showing that CBR-5884 does not inhibit LDH under the drug concentrations used. In sum, the data argue that CBR-5884 is able to selectively inhibit serine synthesis in cells.
Given that CBR-5884 is an ethyl ester and therefore susceptible to intracellular esterases, we investigated whether the carboxylic acid derivative of the parent molecule was still active against PHGDH; were the acid less active, it would likely decrease the efficiency of targeting PHGDH in situ. Parent and acid derivatives were equally potent against, and selective for, PHGDH in vitro, suggesting that intracellular deesterification is unlikely to affect CBR-5884 activity (Fig. S1 ).
CBR-5884 Selectively Inhibits the Proliferation of Cancer Cells with a
High Propensity for Serine Synthesis. We established a system to test the ability of CBR-5884 to inhibit PHGDH-dependent cancer cell proliferation. We first evaluated the ability of a panel of breast and melanoma cell lines to proliferate in serine replete or deplete media as a proxy for serine biosynthetic activity. Breast lines were selected based on PHGDH expression according to the Cancer Cell Line Encyclopedia (CCLE) data and validated by blotting for PHGDH (Fig. 3A and Fig. S2 ) (20) . Removing extracellular serine had no effect on proliferation of high PHGDH-expressing lines MDA-MB-468, MDA-MB-436, HCC70, and Hs578T (Fig. 3B) . All four lines cluster in the top quartile of the CCLE dataset for PHGDH expression (Fig. S2) ; MDA-MB-468 and HCC70 cells harbor PHGDH amplifications (14) . In contrast, serine depletion almost completely abrogated proliferation of low PHGDHexpressing lines MDA-MB-231 and MCF10A (Fig. 3B) . In melanoma cells, PHGDH protein levels were similarly commensurate with the ability to proliferate in serine-free media (Fig.  S2) . Interestingly, although Carney cells are sensitive to extracellular serine depletion, they can adapt and proliferate, as evidenced by increased PHGDH protein levels upon serine depletion (Fig. S2) .
Given that the ability to proliferate in the absence of extracellular serine is indicative of a high propensity for serine synthesis, we hypothesized that such lines should be sensitive to CBR-5884. Conversely, lines that cannot grow in serine-free media have a low propensity for serine synthesis and should therefore be resistant to PHGDH inhibition. Treating the breast lines with CBR-5884 in serine-replete media inhibited growth of the four lines that grew without extracellular serine in a dose-dependent manner, with growth inhibition ranging from 35% to 60% at 30 μM CBR-5884. The inhibitor had no effect on the three lines sensitive to serine withdrawal, indicating that the inhibitor was selectively toxic to cells with high serine synthesis activity (Fig. 3C) . We next asked whether removing serine from the media, to enhance the reliance on de novo serine synthesis, could sensitize cells to PHGDH inhibition. Indeed, serine depletion increased the efficacy of CBR-5884 in lines already sensitive under serine-replete conditions as evidenced by an 80-90% decrease in proliferation with 30 μM CBR-5884 (Fig. 3D) . Moreover, MCF7 cells, which were of intermediate sensitivity to serine withdrawal, and insensitive to drug under serine-replete conditions, became partially sensitive to the inhibitor under serinedeplete conditions (Fig. 3D) . Importantly, under serine-replete conditions, PHGDH knockdown phenocopied the effects of CBR-5884 treatment in that the drug-sensitive lines were also sensitive to The ability of the seven lead PHGDH inhibitors to block serine synthesis was assayed as in A.
13 C 6 -glucose-derived serine (M+3 serine) relative to total serine levels is plotted. (C ) In vitro IC 50 assays for PHGDH and lactate dehydrogenase (LDH). Initial rates of the enzymatic reaction (V i ) at the indicated CBR-5884 concentration normalized to that of the DMSO control (V o ) are plotted. (D) CBR-5884 dose-response experiment as in A, but monitoring a panel of phosphoserine pathway and glycolytic metabolites. The y axes indicate the fraction of the indicated metabolite derived from glucose (M+3 metabolite level relative to total metabolite level). Asterisks indicate significant differences vs. DMSO treatment (P < 0.05, t test, n ≥ 3). Error is given as ±1 SD.
PHGDH knockdown (Fig. 3E and Fig. S2) . Furthermore, as with the drug treatments, growing cells in serine-free media enhanced the growth inhibitory effect of PHGDH knockdown (Fig. 3F) . Similar trends were observed for the melanoma panel in terms of both the selectivity of CBR-5884 for cells with a high propensity for serine synthesis and the increased efficacy under serine-deplete conditions (Fig. S2) . Finally, the acid derivative of compound 5884 was not effective on MDA-MB-468 cells, likely owing to poor membrane permeability, and is therefore not a viable alternative to the parent compound (Fig. S2) .
Analysis of CBR-5884 Inhibition Modality. We sought to more deeply characterize the mechanism by which CBR-5884 inhibits PHGDH. Inhibition constants (K i ) for CBR-5884 with respect to each substrate were determined. CBR-5884 inhibited PHGDH in a noncompetitive mode with respect to both substrates, as evidenced by a decreasing V max with increasing CBR-5884 concentration. The inhibition constants were 50 ± 20 μM and 50 ± 3 μM for 3-PG and NAD + , respectively (Fig. 4 A and B) . We assessed whether there was any time dependence to the onset of inhibition by varying the time period for which drug and PHGDH were preincubated before initiating the enzymatic reaction. CBR-5884 was progressively more potent with increasing preincubation time, culminating in an IC 50 of 7 μM when drug and PHGDH were preincubated for 4 h (Fig. 4C) . Intrigued by the combination of a time-dependent onset of inhibition and noncompetitive inhibition, the latter suggesting that CBR-5884 might be binding to an allosteric pocket, we speculated that CBR-5884 could be affecting the PHGDH oligomerization state, where the time dependency of inhibition could potentially stem from drug-induced conformational changes in PHGDH. To evaluate the PHGDH oligomerization state, we incubated PHGDH with drug and then cross-linked before SDS/PAGE. CBR-5884 shifted the PHGDH equilibrium from the tetrameric to the dimeric state (Fig. 4D) . No such effect was observed with LDH, which is resistant to CBR-5884-mediated inhibition (Fig. S3) . CBR-5884 still inhibited a truncated form of PHGDH, which lacks the C-terminal domain responsible for tetramerization and is therefore a constitutive dimer (Fig. S3) . Together, these results suggest that disruption of the tetramer might assist PHGDH inhibition but is not necessary for inhibition.
Discussion
We have reported the discovery of a PHGDH inhibitor, CBR-5884, and have shown that it inhibits serine synthesis in cells. Furthermore, CBR-5884 specifically inhibited the proliferation of melanoma and breast cancer lines with high levels of serine synthesis activity, with little effect on lines reliant on serine import. Thus, CBR-5884 is selective for lines addicted to serine synthesis and phenocopies sensitivity to PHGDH knockdown. Finally, a biochemical analysis of CBR-5884 revealed that it was a noncompetitive inhibitor that showed a time-dependent onset of inhibition and disrupted the oligomerization state of PHGDH.
Recent work examining how malignant cells rewire their metabolism to support growth and proliferation has revealed a number of clinically interesting targets (21, 22) . Perhaps the most promising is the discovery of gain-of-function mutations in the isocitrate dehydrogenase (IDH) enzymes that result in the production of the oncometabolite 2-hydroxyglutarate (23, 24) . The findings translated into chemical probes that yielded insights into the biology of IDH mutations (25, 26) and led to clinical programs (e.g., NCT02481154). The genetic evidence pointing to a role for PHGDH in cancer is similarly striking: PHGDH is one of few metabolic enzymes genetically deregulated in cancer (27, 28) . Notably, elevated PHGDH expression correlates with clinical aggressiveness and poor prognosis in TNBC (13, 16) and NSCLC (15) . There is a paucity of targeted therapies for these cancers and chemotherapies are frequently used (29, 30) . Thus, the clinical potential of PHGDH inhibitors as targeted agents for TNBC and NSCLC tumors addicted to serine synthesis, as a single agent or in combination with standard of care, is an exciting perspective. Beyond the preclinical applications, a PHGDH inhibitor provides a tool to study de novo serine synthesis. For example, it remains unclear why a serine biosynthesis enzyme is critical for tumor growth when serine is available in the serum (13, 14) . CBR-5884 provides a valuable tool complementary to genetic strategies to study the necessity of serine synthesis and other phenomena because small molecules provide greater temporal resolution and do not deplete the actual protein. Moreover, CBR-5884 has already suggested an interesting feature of PHGDH biochemistry: namely, that human PHGDH could be regulated by transitions between different oligomerization states. These findings are reminiscent of pyruvate kinase M2 (PKM2) regulation in that both an endogenous metabolite, fructose-1,6-bisphosphate, and pharmacological small molecule activators enhance PKM2 activity by stabilizing the tetrameric form (31, 32) . Endogenously, 2-phosphoglycerate (2-PG) has been reported to activate PHGDH (33) . Mechanistically, 2-PG could be functioning by modulating the PHGDH oligomerization state. Finally, it is possible that CBR-5884 is a covalent inhibitor of PHGDH. Although PHGDH does not rely on an active site cysteine, there are a number of cysteines that could potentially perturb enzymatic function were they modified because they are in close proximity to the active site (PDB ID code 2G76).
In an attempt to determine whether changes in the PHGDH oligomerization state are unique to CBR-5884, it would be interesting to determine whether Disulfiram (CBR-5807), CBR-6936, or sulfhydryl blocking reagents have similar effects.
The identification of a selective small molecule inhibitor of PHGDH capable of modulating de novo serine synthesis in PHGDH-dependent cancer cells represents a significant step toward the goal of targeting serine metabolism in oncology. However, future in vivo evaluation of the CBR-5884 chemical series will require medicinal chemistry-based optimization. Indeed, CBR-5884 was found to be unstable in mouse plasma, and, as described, replacement of the ethyl ester moiety with the corresponding negatively charged carboxylic acid resulted in a derivative that retains enzyme inhibitory activity but loses activity on cells. Thus, CBR-5884 is more likely to serve as a tool compound, and as a starting point for generating more drug-like molecules, than an actual drug. Furthermore, the cell-based potency of this series will likely need to be improved to enable in vivo evaluation at exposure levels that are not generally toxic. Nevertheless, our results provide a proof-of-concept that small molecule inhibitors of PHGDH represent a viable class of anti-cancer drugs.
Methods
Cells, Transfections, and Infections. Breast and melanoma lines were passaged in RPMI supplemented with 10% (vol/vol) FBS, penicillin, streptomycin, and normocin (InvivoGen). Lentivirus was produced from Lenti-X 293T cells (Clontech) transfected with packaging plasmids pCMV-dR8.2 and pCMV-VSV-G and indicated pLKO.1 shRNAs: PHGDH, TRCN0000233029 (sh1) and TRCN0000221864 (sh2); nontargeting control, TRCN0000072181 (shGFP). Experiments were performed in compliance with Weill Cornell Medicine Environmental Health and Safety and Institutional Biosafety Committee. See SI Methods for details.
Immunoblots. Protein was extracted from cells via trichloroacetic acid precipitation and blotted for with primary antibodies αPHGDH (HPA021241, 1/10,000; Sigma) and αVinculin (V9264, 1/5,000; Sigma). See SI Methods for details.
Proliferation Assays. Cells were plated at a low density in 96-or 24-well plates in serine containing media. The following day, media were aspirated, cells were washed with PBS, and fresh serine-replete or -deplete media containing drug (15 μM, 30 μM) or vehicle (DMSO) were added. Cells were grown for 3-5 d, with drug and media changed daily before assaying relative cell numbers. See SI Methods for details.
Acute Drug Treatments with 13 C 6 -Glucose Tracing. Carney cells acclimated to growth in MEM (Corning) were plated at 9 × 10 5 cells per 6-cm dish the night before. The following morning, media were replaced with fresh media containing CBR-5884 (1 μM, 15 μM, 30 μM) or vehicle control (DMSO) for 1 h. Media were then aspirated, cells were washed with PBS, and fresh glucosefree MEM (Gibco) supplemented with 13 C 6 -glucose (3 g/L; Cambridge Isotopes) and 10% (vol/vol) dialyzed FBS containing drug or DMSO was added. After 2 h, cells were quickly washed with cold PBS on ice and flash frozen. Polar metabolites were extracted as in the GCMS methods. See SI Methods for details.
Acute Toxicity Assay. Carney cells acclimated to growth in MEM media were plated in a 96-well plate at 6,000 cells per well. The next day, cells were treated with CBR-5884 from 1 μM to 40 μM for 3 h. Drug containing media were then removed, fresh drug-free media added, and cell viability was determined via a CellTiter-Glo (G7572; Promega) or Alamar Blue (DAL1025; Invitrogen) assay according to the manufacturer's protocol. See SI Methods for details.
GCMS Metabolite Analysis. Polar metabolites were extracted with 2 mL of MeOH/H 2 O (4:1) for 30 min on dry ice, scraped, transferred to 2-mL tubes, and centrifuged (30 min, 21,000 × g), and the supernatants were dried under A B C D Fig. 4 . Mechanisms of CBR-5884 inhibition. Inhibition constants (K i ) were determined by titrating (A) 3-PG or (B) NAD + while holding the other substrate constant at four different CBR-5884 concentrations and determining the initial reaction rate using a PHGDH assay. Plots were fit to a noncompetitive model. (C) Timedependent inhibition was measured by preincubating drug and PHGDH for 0.5 h, 1 h, or 4 h as indicated before initiating the PHGDH reaction. Initial reaction rates (V i ) were determined and normalized to that of DMSO (V o ). (D) PHGDH was preincubated with CBR-5884 (0, 50, 200, or 400 μM) before cross-linking with BS3 (0.25 or 2.5 mM) followed by SDS/PAGE and Coomassie staining. Leftmost lane had no BS3 indicating the monomeric species. Oligomerization state was inferred from reference to a molecular weight ladder. Error is given as ±1 SD (n ≥ 3).
vacuum. Samples were derivatized as previously described (34) and analyzed on an Agilent 6890 GC instrument. Metabolite quantification was inferred from a standard curve, and fractional enrichment of 13 C in metabolites was corrected for the natural abundance of 13 C and 15 N (35, 36) . See SI Methods for details.
LC-MS/MS Metabolite Analysis. Polar metabolites were extracted and dried as in the GCMS method. Samples were resuspended in 15 μL of HPLC grade water. Then, 5 μL of each sample was injected and analyzed using a 5500 QTRAP triple quadrupole mass spectrometer (AB/Sciex) coupled to a Prominence UFLC system (Shimadzu) as reported previously (37) .
